Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics, Inc. (NASDAQ:APRE) presented initial clinical data on ATRN-119 and pre-clinical data on ATRN-1051 at the AACR-NCI-EORTC International Conference. The data includes first-in-human clinical data from the ongoing Phase 1 dose escalation trial of ATRN-119, and pre-clinical data from the WEE1 inhibitor, ATRN-1051. The company plans to submit an IND for ATRN-1051 in Q4 2023. ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors, with no hematologic or liver function toxicities observed so far. The company anticipates dose expansion of the trial in Q2 2024.
October 16, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics presented positive initial clinical and pre-clinical data on ATRN-119 and ATRN-1051 respectively. The company plans to submit an IND for ATRN-1051 in Q4 2023 and anticipates dose expansion of the ATRN-119 trial in Q2 2024.
The positive initial clinical and pre-clinical data presented by Aprea Therapeutics for ATRN-119 and ATRN-1051 respectively, along with the planned IND submission for ATRN-1051 in Q4 2023 and anticipated dose expansion of the ATRN-119 trial in Q2 2024, are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100